Key facts
- Karius’s last known valuation is $185.0M.
- It has raised $409.3M; the latest was Later Stage VC ($100.0M) in May 2024.
- Notable investors include General Catalyst, Khosla Ventures, Lightspeed Venture Partners, StartX (US), SoftBank Investment Advisers — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Karius
- ·The full record, as it builds
Funding rounds
No funding rounds for Karius are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Karius
Operator of a clinical laboratory testing center intended to generate genomic insights for infectious diseases. The company's tests map each patient's microbial landscape from a single blood draw and develop molecular biology and data analysis tools that use deep sequencing to detect minuscule traces of microbial deoxyribonucleic acid directly from blood, enabling physicians to make rapid life-saving treatment decisions in a hassle-free manner.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2014
- Employees
- 180
- Website
- kariusdx.com/
- Ownership
- Privately Held (backing)
Karius doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Karius shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Karius in its N-PORT filings yet. We sweep new filings monthly.